Oncology trends: Breast cancer leads Twitter mentions in Q4 2020
Source : https://www.pharmaceutical-technology.com/features/oncology-trends-breast-cancer/
The top tweeted terms are the trending industry discussions happening on Twitter by key individuals (influencers) as tracked by the platform. Covid-19 leading to delay in cancer diagnoses, the road...
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
Source : https://www.sciencedirect.com/science/article/abs/pii/S1470204520307026
Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER...
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
Background: Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) are widely used as first-line therapy for hormone receptor-positive metastatic breast cancer (HR+ MBC). Although abemaciclib monotherapy is also FDA-approved for...
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33523233/
doi: 10.1093/jnci/djab004. Online ahead of print. 1 University of Pittsburgh Medical Center, Hillman Cancer Center/Magee Women's Hospital, Pittsburgh, PA. 2 Genentech, Inc., South San Francisco, CA. 3 Peter MacCallum Cancer...